On the fly News and insights, exclusive to thefly.com

EIDX

Eidos Therapeutics

$55.16

8.58 (18.42%)

, BBIO

BridgeBio

$29.06

0.8 (2.83%)

05:07
11/19/19
11/19
05:07
11/19/19
05:07

Eidos Therapeutics price target raised to $75 from $55 at Piper Jaffray

Piper Jaffray analyst Tyler Van Buren raised his price target for Eidos Therapeutics to $75 from $55 and reiterates an Overweight rating on the shares following the initial AG10 long-term outcomes data. The stock closed Monday up 18% to $55.02. After speaking with a key opinion leader, the analyst believes that BridgeBio (BBIO) and Eidos's AG10 appears superior to the anticipated blockbuster Vyndaqel/tafamidis. Van Buren says he's using a "conservative" one-times multiple on a 2030 AG10 sales estimate. He believes the ATTR cardiomyopathy market could grow to an eventual $5B-$10B opportunity as the pool of diagnosed patients expands several-fold. In addition, the new price target does not include a premium for a takeout, which is more likely following the AG10 data, Van Buren tells investors in a research note.

EIDX

Eidos Therapeutics

$55.16

8.58 (18.42%)

BBIO

BridgeBio

$29.06

0.8 (2.83%)

  • 21

    Nov

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.